Navigation Links
American Oriental Bioengineering Announces Participation in November Investor Conferences
Date:10/31/2008

NEW YORK, Oct. 31 /Xinhua-PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB) ("AOBO"), a leading marketer, distributor and manufacturer of pharmaceutical and healthcare products in China, today announced that the Company will present at the following conferences:

-- Oppenheimer 19th Annual Healthcare Conference, held at the Waldorf-

Astoria in New York. Management is currently scheduled to present at

8:40 am ET on Tuesday, November 4, 2008.

-- Credit Suisse Asia Healthcare Conference, held at the Westin in Beijing.

Management is currently scheduled to present at 4:30 pm local time on

Wednesday, November 5, 2008;

-- Morgan Stanley 2008 Asia Pacific Summit, held at the Mandarin Oriental

in Singapore. Management is currently scheduled to present at 3:15 pm

local time on Wednesday, November 12, 2008;

-- Oppenheimer 4th Annual 'Best Ideas' Conference, held at the Millennium

Broadway in New York. Management is currently scheduled to present at

1:20 pm ET on Tuesday, November 18, 2008. A webcast of this

presentation will be available via the Company's website at

http://www.bioaobo.com .

-- Lazard 5th Annual Healthcare Conference, held at the St. Regis in New

York. Management is currently scheduled to present at 11:30 am ET on

Wednesday, November 19, 2008.

For more details on the conferences, please contact your respective institutional sales representative.

About American Oriental Bioengineering Inc.

American Oriental Bioengineering Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products in China.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-Q for the quarter ended June 30, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.


'/>"/>
SOURCE American Oriental Bioengineering Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
3. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
4. American Oriental Bioengineering Announces Participation in September Investor Conferences
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
7. Tips from the Journals of the American Society for Microbiology
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
10. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
11. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... the three months ended December 31, 2016. ... and diagnostics company that develops and commercializes proprietary technologies and ... ... the commercial milestones achieved in fiscal 2016," said Andrew ...
(Date:2/21/2017)... ... 21, 2017 , ... Genedata, a leading provider of advanced ... establishment of Genedata Limited as a new subsidiary in the United Kingdom. The ... science informatics. Creating the UK subsidiary reinforces Genedata’s commitment to collaborate closely with ...
(Date:2/21/2017)... IL (PRWEB) , ... February ... ... of the Life -Sciences division, Treximo will pair its $200M operational capacity ... results-based consulting and project management in areas affecting quality and operational management. ...
(Date:2/21/2017)... VANCOUVER, British Columbia , Feb. 21, 2017 /PRNewswire/ ... that apatorsen results from two randomized Phase 2 clinical trials ... 2017 Genitourinary Cancers Symposium, held February 16 th - 18 ... from trials in bladder and prostate cancers demonstrated apatorsen was ... standard-of-care treatments. ...
Breaking Biology Technology:
(Date:2/3/2017)...  Texas Biomedical Research Institute announced that its Board of ... as the Institute,s new President and CEO. Dr. Schlesinger will ... He is currently the Chair of the Department of Microbial ... Interface Biology at Ohio State University. "We are ... CEO of Texas Biomed," said Dr. James O. Rubin ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to ... and meaningful advances worldwide, The Japan Prize Foundation ... Prize, who have pushed the envelope in their ... and Communication. Three scientists are being recognized with ... achievements that not only contribute to the advancement ...
Breaking Biology News(10 mins):